Pediatricians often watch for signs that one illness might signal another. One example of linked health issues is the ...

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses treatment approaches for atopic dermatitis of the face in infancy, which he presented at the Revolutionizing ...

Recognizing atopic dermatitis, getting it into remission, then keeping control can be challenging for both clinicians and caregivers. We hope these five key messages for general and specialist care ...

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses best practices that physicians and parents of infants with atopic dermatitis (AD) can do to help manage flare ...

L iving with atopic dermatitis can be challenging for anyone, but if someone you love has eczema, it can be particularly tough. About 13 percent of children in the United States have atopic dermatitis ...

The U.S. Food and Drug Administration has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD). The approval is the first topical Janus kinase (JAK) ...

Please provide your email address to receive an email when new articles are posted on . There is no gold standard for evaluating atopic dermatitis among infants with different skin tones. Photographs ...

Primary care physicians (PCPs) play a key role in treating young patients as they progress through the "atopic march" from atopic dermatitis through food allergy, asthma, and allergic rhinitis. They ...

Please provide your email address to receive an email when new articles are posted on . AD onset in infants was significantly delayed with high vs. low dietary diversity during pregnancy. There was a ...

Use of antibiotics early in life was linked to an increased risk of atopic dermatitis, likely driven by gut microbiome disruption, according to data from the Canadian CHILD birth cohort. Use of ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA ...